MENLO PARK, Calif.–(BUSINESS WIRE)–AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended September 30, 2023. “We are incredibly proud of the significant milestones achieved recently and over…
Click here to view original post
Copyright © 2023 Biotech Networks, LLC
